Aim of study : The aim of this study was to determine the interleukin levels in patients having prostate cancer surgery.Patients and Methods: The current data was collected for referred patients from March 2023 to October 2023 at the Iraqi Center of Cancer and Medical Genetics Research, Using sandwich ELISA kits, the levels of the cytokines IL-6 and IL-8 were assessed in serum of 25 healthy, normal controls and 50 prostate cancer patients undergoing treatment.Every participant in the study had to be at least 40 years old. Men with a PSA of less than 4 ng/ml and no history of prostate cancer served as controls. Male patients receiving androgen deprivation therapy had a histological diagnosis of prostate cancer.Results :the number of prostate cancer patients with surgical treatment was highest (P < 0.05) in the age group of 61≤ years (25 , 41.6%), followed by the age group of 51- 60 years (21 , 35 %) , So serum IL-6 was significantly higher (33.91 ±2.81 pg/ml) in patients without surgical treatment as compared to patients with surgical treatment (27.01±3.31) However,Serum IL-8 was significantly higher (203.9 ±3.82 pg/ml) in patients without surgical treatment as compared to patients with surgical treatment (118.10 ±4. 99)as well as in control group (71.872±31.22 pg/ml).Conclusion: Both IL-6 and IL-8 are important biomarkers in the context of prostate cancer. Their levels can provide insights into disease status and treatment response. Monitoring these cytokines may help in assessing the effectiveness of surgical interventions and in understanding the underlying inflammatory processes in prostate cancer patients.

Key words : PSA, prostate cancer, age specific PSA, reference range